Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar

Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

Zydus receives final approval from USFDA for Ammonium Lactate Cream, 12%

FDA nod to Acrotech's new eczema treatment

ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility

Inspection included drug device combinations covering our recent filing in nasal sprays domain

Lupin launches Dasatinib tablets in US, eyes $930 million oncology market

Indoco Remedies bags USFDA nod for Lacosamide oral solution

The approved Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference drug and will be manufactured at Indoco’s facility in Verna Industrial Area, Goa

Biocon Biologics gets credit boost from S&P, outlook stable

The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’

Biocon completes Rs. 4,150 crore equity fundraise through QIP

The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited